ERBB2 and cancer: We believe this is due to the high proportion of HER2-positive luminal cancer patients, with pCR found in only 33.3% (vs. 66.7% in ER-negative, HER2-positive patients), and the significantly lower chance of pCR observed in our patients aged 60 years and older, compared with younger patients (11.1% vs. 89.9%).